Drug survival rates for tumour necrosis factor-α antagonists in psoriasis

Determinants of drug survival for etanercept in a long‐term daily practice cohort of patients with psoriasis

“…Gniadecki et al found a comparable overall 4-year drug survival for 331 treatment episodes with etanercept (~40%) and comparable numbers of reasons for discontinuation of etanercept: 98 patients discontinued etanercept (36%); the majority of patients discontinued due to lack of effectiveness (27%) and a minority because of side-effects (4%). 8,10 They found that previous failure on one or more anti-TNF agents (HR 5Á3) and female sex (HR~2) were determinants of poor drug survival. 10 Esposito et al found an overall drug survival rate of 72Á6% after 2 years (not split per agent); predictors of shorter drug survival were female sex (HR 1Á3) and the concomitant use of traditional systemic treatment (HR 1Á9).…”

“…8 It is dependent on a combination of factors such as drug effectiveness, treatment or patient satisfaction, the availability of other treatment options and the occurrence of severe or disturbing sideeffects. 8,10 Data on drug survival for biological agents in psoriasis are scarce. Gniadecki et al and Esposito et al have investigated and compared the drug survival rates for different biologics.…”

“…Registry data are ideal for identifying common characteristics, effectiveness and safety of biologics in real-world practice. 8,9 Since 2005, our department has been collecting data in a prospective database of all patients using biologics (including etanercept) for plaque psoriasis. The extended follow-up in our registry makes it possible to focus on long-term drug survival rates for etanercept.…”

Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis

“…3,4 Treatment will be more often continued despite side-effects or a moderate response when no other treatment options are left. In the present study, CsA was the first oral immunosuppressive drug used in 80Á6% of the patients.…”

“…4,5 To our knowledge, this is the first study on drug survival for CsA treatment in adult patients with AD. The primary objective of our study was to perform a detailed analysis of drug survival for CsA in a long-term daily practice cohort of patients with severe AD.…”